Edgewise (EWTX) | Financial Analysis & Statements
Edgewise Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-56.0M
Net Income
-50.2M
EPS (Diluted)
$-0.47
Balance Sheet Metrics
Total Assets
552.6M
Total Liabilities
30.3M
Shareholders Equity
522.3M
Debt to Equity
0.06
Cash Flow Metrics
Operating Cash Flow
-40.3M
Free Cash Flow
-38.7M
Revenue & Profitability Trend
Edgewise Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 151.4M | 127.0M | 90.9M | 54.0M | 32.2M |
| Selling, General & Administrative | 40.0M | 31.9M | 23.5M | 17.6M | 11.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 191.4M | 158.8M | 114.4M | 71.7M | 43.2M |
| Operating Income | -191.4M | -158.8M | -114.4M | -71.7M | -43.2M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 23.6M | 25.0M | 14.2M | 4.0M | 402.0K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -167.8M | -133.8M | -100.2M | -67.6M | -42.8M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -167.8M | -133.8M | -100.2M | -67.6M | -42.8M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -189.1M | -156.5M | -112.6M | -71.1M | -42.9M |
| EPS (Basic) | - | $-0.42 | $-1.57 | $-1.26 | $-1.14 |
| EPS (Diluted) | - | $-0.42 | $-1.57 | $-1.26 | $-1.14 |
| Basic Shares Outstanding | - | 94721769 | 63723600 | 53593753 | 37526332 |
| Diluted Shares Outstanding | - | 94721769 | 63723600 | 53593753 | 37526332 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Edgewise Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 61.1M | 41.7M | 86.1M | 22.0M | 15.6M |
| Short-term Investments | 469.0M | 428.5M | 232.3M | 330.0M | 265.2M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 13.3M | 5.3M | 8.6M | 5.1M | 3.0M |
| Total Current Assets | 543.4M | 475.5M | 327.0M | 357.0M | 283.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 5.5M | 5.3M | 5.7M | 3.3M | 1.3M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 262.0K | 348.0K | 251.0K | 548.0K |
| Total Non-Current Assets | 9.2M | 11.3M | 13.0M | 10.1M | 1.5M |
| Total Assets | 552.6M | 486.8M | 340.0M | 367.1M | 285.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 6.0M | 5.6M | 4.0M | 6.1M | 3.8M |
| Short-term Debt | 1.0M | 996.0K | 980.0K | 608.0K | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 27.4M | 23.9M | 16.8M | 16.6M | 10.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.0M | 3.7M | 4.4M | 3.8M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | 329.0K |
| Total Non-Current Liabilities | 3.0M | 3.7M | 4.4M | 3.8M | 329.0K |
| Total Liabilities | 30.3M | 27.6M | 21.2M | 20.4M | 10.8M |
| Equity | |||||
| Common Stock | 10.0K | 9.0K | 7.0K | 6.0K | 5.0K |
| Retained Earnings | -546.4M | -378.6M | -244.8M | -144.6M | -77.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 522.3M | 459.2M | 318.8M | 346.7M | 274.4M |
| Key Metrics | |||||
| Total Debt | 4.0M | 4.7M | 5.4M | 4.4M | 0 |
| Working Capital | 516.0M | 451.6M | 310.2M | 340.4M | 273.3M |
Balance Sheet Composition
Edgewise Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -167.8M | -133.8M | -100.2M | -67.6M | -42.8M |
| Depreciation & Amortization | 2.3M | 2.3M | 1.7M | 538.0K | 272.0K |
| Stock-Based Compensation | 34.8M | 24.7M | 17.6M | 10.9M | 4.4M |
| Working Capital Changes | -476.0K | 1.5M | -196.0K | 4.2M | 4.3M |
| Operating Cash Flow | -131.3M | -105.3M | -81.1M | -52.0M | -33.9M |
| Investing Activities | |||||
| Capital Expenditures | -256.0K | -1.3M | -5.7M | -5.5M | -668.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -527.2M | -477.1M | -255.9M | -292.4M | -288.2M |
| Investment Sales | 494.7M | 293.7M | 364.5M | 227.4M | 46.6M |
| Investing Cash Flow | -32.8M | -184.7M | 102.9M | -70.6M | -242.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 187.4M | 238.9M | 52.5M | 128.9M | 186.0M |
| Free Cash Flow | -144.1M | -110.3M | -97.7M | -58.2M | -34.2M |
| Net Change in Cash | 23.3M | -51.1M | 74.3M | 6.4M | -90.1M |
Cash Flow Trend
Edgewise Key Financial Ratios
Valuation Ratios
Forward P/E
-13.75
Price to Book
6.55
PEG Ratio
-13.75
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-34.19%
Return on Assets
-23.02%
Financial Health
Current Ratio
19.85
Debt to Equity
0.76
Beta
0.25
Per Share Data
EPS (TTM)
$-1.63
Book Value per Share
$4.92
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EWTX | 3.4B | - | 6.55 | -34.19% | 0.00% | 0.76 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






